Your browser is no longer supported. Please, upgrade your browser.
NVS [NYSE]
Novartis AG
Index- P/E20.87 EPS (ttm)3.96 Insider Own9.30% Shs Outstand2.24B Perf Week-0.25%
Market Cap205.10B Forward P/E12.24 EPS next Y6.75 Insider Trans0.00% Shs Float2.10B Perf Month-9.80%
Income8.98B PEG2.66 EPS next Q1.64 Inst Own10.00% Short Float0.27% Perf Quarter-10.52%
Sales51.56B P/S3.98 EPS this Y14.20% Inst Trans-1.73% Short Ratio3.09 Perf Half Y-5.45%
Book/sh24.09 P/B3.43 EPS next Y6.96% ROA7.10% Target Price103.33 Perf Year-5.19%
Cash/sh2.16 P/C38.29 EPS next 5Y7.84% ROE16.70% 52W Range77.04 - 98.52 Perf YTD-12.54%
Dividend3.20 P/FCF43.75 EPS past 5Y4.10% ROI8.80% 52W High-16.82% Beta0.59
Dividend %3.87% Quick Ratio0.60 Sales past 5Y-0.20% Gross Margin70.70% 52W Low6.37% ATR1.02
Employees109000 Current Ratio0.80 Sales Q/Q14.40% Oper. Margin21.20% RSI (14)21.51 Volatility0.80% 0.92%
OptionableYes Debt/Eq0.66 EPS Q/Q59.30% Profit Margin17.40% Rel Volume1.47 Prev Close82.59
ShortableYes LT Debt/Eq0.49 EarningsJul 21 BMO Payout77.60% Avg Volume1.81M Price81.95
Recom2.00 SMA20-5.28% SMA50-8.89% SMA200-8.74% Volume1,378,683 Change-0.77%
Sep-20-21Downgrade Deutsche Bank Hold → Sell
Mar-22-21Initiated Bernstein Mkt Perform
Mar-10-21Downgrade Argus Buy → Hold
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Sep-24-21 08:27AM  
Sep-22-21 07:34AM  
Sep-21-21 01:23PM  
09:46AM  
07:07AM  
01:36AM  
Sep-20-21 10:03PM  
12:40PM  
Sep-19-21 07:35AM  
07:30AM  
Sep-17-21 07:30AM  
06:51AM  
Sep-16-21 06:05PM  
11:43AM  
11:02AM  
Sep-13-21 11:35AM  
Sep-08-21 07:01PM  
07:30AM  
Sep-07-21 01:49PM  
Sep-01-21 06:23AM  
Aug-31-21 07:01PM  
07:01PM  
Aug-30-21 01:15AM  
Aug-25-21 03:18PM  
Aug-24-21 11:57AM  
01:15AM  
Aug-17-21 06:17AM  
Aug-04-21 11:58AM  
09:34AM  
09:16AM  
Aug-03-21 01:15AM  
Aug-02-21 09:30AM  
08:04AM  
Jul-28-21 09:59AM  
07:25AM  
Jul-27-21 11:14AM  
Jul-26-21 02:53PM  
Jul-23-21 08:01AM  
Jul-22-21 12:25PM  
08:38AM  
Jul-21-21 08:31PM  
05:04PM  
04:24PM  
04:22PM  
05:07AM  
01:20AM  
Jul-20-21 08:00PM  
08:38AM  
07:05AM  
Jul-15-21 07:12AM  
Jul-13-21 06:55AM  
Jul-12-21 06:12AM  
Jul-09-21 08:01AM  
Jul-08-21 09:04AM  
Jul-06-21 04:42AM  
Jul-01-21 03:08PM  
Jun-29-21 03:17PM  
11:11AM  
09:57AM  
09:52AM  
Jun-28-21 11:31AM  
05:05AM  
01:00AM  
Jun-23-21 11:11AM  
Jun-21-21 07:24AM  
Jun-18-21 12:30PM  
Jun-17-21 06:44AM  
06:00AM  
06:00AM  
Jun-16-21 09:57AM  
Jun-14-21 04:20PM  
Jun-11-21 08:41AM  
03:00AM  
Jun-09-21 08:41AM  
Jun-07-21 12:39PM  
09:38AM  
Jun-06-21 06:06AM  
Jun-04-21 03:10PM  
01:08PM  
09:05AM  
09:00AM  
Jun-03-21 09:00PM  
05:05PM  
03:21PM  
12:04PM  
Jun-02-21 09:05AM  
09:00AM  
07:05AM  
07:02AM  
01:15AM  
Jun-01-21 04:30PM  
08:15AM  
May-28-21 04:30PM  
08:48AM  
May-27-21 04:55PM  
03:08PM  
12:08PM  
08:19AM  
01:15AM  
May-25-21 04:47PM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.